Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HNF4A | P41235 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27648103 | 0.87 | KDM4E (0.48) | KDM4EHNF4AKMOALDH1A1MAPT | |
| SCHEMBL1885886 | 0.83 | NOTUM (0.53) | KDM4ECYP3A4CYP2C9ALDH1A1MAPT | |
| SCHEMBL1878128 | 0.75 | SCN9A (0.49) | KDM4E | |
| SCHEMBL14692532 | 0.75 | KDM4E (0.48) | KDM4EKMO | |
| SCHEMBL19991300 | 0.74 | KDM4E (0.49) | KDM4E | |
| SCHEMBL20162909 | 0.74 | KDM4E (0.49) | KDM4E | |
| SCHEMBL27655886 | 0.74 | KDM4E (0.56) | KDM4EALDH1A1 | |
| SCHEMBL2774450 | 0.74 | KDM4E (0.49) | KDM4EALDH1A1 | |
| SCHEMBL29367242 | 0.74 | KDM4E (0.49) | KDM4E | |
| SCHEMBL27647990 | 0.73 | MEN1 (0.52) | KDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2009-08-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | GABRB1, GABRB2, GABRB3 | KDM4E 2635/4885NR1H2 712/4885HNF4A 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.